In the beginning of May, 2022, it was announced that Navamedic is acquiring Impolin AB, which significantly strengthens Navamdic’s position in the market for obesity treatment in the Nordics.
The addition of Impolin’s portfolio of weight loss products, Modifast and MedMade, significantly broadens Navamedic’s product offering within the area of obesity treatment and enables Navamedic to support patients throughout the entire weight loss journey.
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com